Johnson & Johnson (JNJ)

140.23
0.79 0.57
NYSE : Health Technology
Prev Close 139.44
Open 140.56
Day Low/High 139.79 / 140.93
52 Wk Low/High 120.11 / 148.99
Volume 6.97M
Avg Volume 6.59M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 371.95B
EPS 5.70
P/E Ratio 25.94
Div & Yield 3.80 (2.59%)

Underperformer J&J Does It Again

Dow Jones Industrial Average member Johnson & Johnson is lower in pre-market trading. The reason? The drug maker took a page out of IBM's playbook by recording a much lower effective tax rate in the quarter (14.5% vs. 18%), which on an adjusted basi...

What to Watch Tuesday: Verizon, Lockheed Martin Report Earnings

What to Watch Tuesday: Verizon, Lockheed Martin Report Earnings

On Tuesday, January 24, investors await a host of quarterly earnings reports.

What to Watch This Week: Trump's Presidency, Alphabet Earnings

What to Watch This Week: Trump's Presidency, Alphabet Earnings

For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

Intermediate Trade: Johnson & Johnson

Intermediate Trade: Johnson & Johnson

After an up-and-down year, this household name is as strong as ever.

Biotech Sector to See M&A, Earnings Action

Biotech Sector to See M&A, Earnings Action

Deals already are popping up, and we'll soon have earnings reports from the industry giants.

Here's the Company That Helped Design Work Spaces for Facebook and Microsoft

Here's the Company That Helped Design Work Spaces for Facebook and Microsoft

We toured the company helping design cool workspaces for Fortune 500 companies like Facebook and Microsoft.

Here's Why Johnson & Johnson Shares Are Poised for a Rally

Here's Why Johnson & Johnson Shares Are Poised for a Rally

Shares of Johnson & Johnson are poised for a rally as the stock is currently trading about 8% off its 52-week high.

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson Could Benefit From Tax Reform

Johnson & Johnson could repatriate offshore profits in 2017 if a potential tax holiday is passed.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Shares of J&J and Procter & Gamble Could Be Ready to Break Out

Shares of J&J and Procter & Gamble Could Be Ready to Break Out

After a period of consolidation, several personal care products companies look like they are about to rally.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Cramer: Too Few Stocks Are Doing Too Much in Dow's Run to 20,000

Disney and Goldman are doing a lot of the heavy lifting.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Damage Award Against Johnson & Johnson Cut in Half by Judge

Damage Award Against Johnson & Johnson Cut in Half by Judge

A big damage award against J&J has been reduced by a judge, but the company is still facing thousands of additional claims.

Watch Beaten-Down Drug Companies, Hospitals in 2017

Watch Beaten-Down Drug Companies, Hospitals in 2017

There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.

Top 5 Dividend Stocks to Buy Now for 2017

Top 5 Dividend Stocks to Buy Now for 2017

Here is a look at some stocks that are poised for excellent dividend returns in 2017.

Jim Cramer on Why Johnson & Johnson Returned to Actelion Talks

Jim Cramer on Why Johnson & Johnson Returned to Actelion Talks

Jim Cramer wonders whether someone at Johnson & Johnson is now willing to pay more for Actelion, or if there was more give from the other side.

Dow Goes Down, Boeing Cuts Costs and Actelion Talks Transition

Dow Goes Down, Boeing Cuts Costs and Actelion Talks Transition

This is what you need to know before the opening bell on Thursday.

Good Time to Sell Russell 2000 Puts

Good Time to Sell Russell 2000 Puts

The Fed seems to have aligned itself with the new emerging themes of financials and small-caps.

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.

Takeaways and Observations

The markets moved lower from the "get go," though about the time Sixty Minutes was on last evening the S&P 500 futures were up 10 handles. (Futures closed down 2.5 handles)   Perhaps this is the start of a well due correction. Apropos, here is the q...

This Isn't a Bearish Pause in the Market

This Isn't a Bearish Pause in the Market

It's simply a little consolidation after a huge run. But could it develop?

Beware the Fear of Missing Out (FOMO)

Beware the Fear of Missing Out (FOMO)

There's a striking lack of volatility, and that's a flashing red warning signal.

Cramer: Effect of News on These Companies Is Positively Stunning

Cramer: Effect of News on These Companies Is Positively Stunning

But who are these buyers? Where are the sellers?

Jim Cramer Comments on J&J's Potential Deal With Actelion

Jim Cramer Comments on J&J's Potential Deal With Actelion

Jim Cramer is watching Johnson & Johnson, which may buy a Swiss drugmaker. Cramer says it's important to see how the deal is structured.

Have Traders in Johnson & Johnson Recently Turned Bullish?

Have Traders in Johnson & Johnson Recently Turned Bullish?

This stock needs more aggressive buying before it is an outright long.

Johnson & Johnson downgraded at Barclays

My Takeaways and Observations (3:30 p.m. Edition)

It may be time to embrace the contrary.    First issue (!!): The Palm Beach Chronicles.   My weekly (brief) technical review of the markets -- cooling off ahead?    BTIG's Stockton is bullish and so, as I have expressed, are most others!   Campbell ...

No More Tears: How to Play a Likely Johnson & Johnson Rally

No More Tears: How to Play a Likely Johnson & Johnson Rally

Technical support and statistical evidence suggest the stock will rebound.